Spatial and Temporal Tracking of Counterfeit Phosphodiesterase Type V Inhibitors Use Based on Wastewater Analysis
Abstract
Phosphodiesterase type V inhibitors (PDE-5is) are widely used for the treatment of erectile dysfunction, and global demand for these pharmaceuticals continues to grow. However, the circulation of unlicensed and counterfeit PDE-5is poses serious public health risks. This study employed solid-phase extraction coupled with LC-MS/MS to analyze 116 influent wastewater samples collected in Dalian, China, in order to assess the temporal and spatial trends in the community-level use of counterfeit PDE-5is. Among the three target compounds, neither tadalafil nor vardenafil was detected in any sample. Sildenafil, however, was found in 94.5% of the samples, with concentrations ranging from below the limit of quantification (LOQ) to 75.4 ng/L. Its major metabolite, desmethylsildenafil, was detected in concentrations ranging from < LOQ to 107 ng/L. Sildenafil consumption steadily increased between 2017 and 2022 (40.8 to 87.8 mg/d/1000 inh). Notably, the estimated consumption based on wastewater data far exceeded local prescription sales, which accounted for only approximately 20% of the total use, with counterfeit sildenafil use estimated to exceed 100 kg/year in Dalian. This discrepancy indicates that the majority of sildenafil is obtained through over-the-counter sales or illegal channels. For spatial analysis, wastewater treatment plants were classified according to the characteristics of the populations they served. Sildenafil consumption was substantially higher in urban areas (70.4…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.